Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

Article

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

Fabrice Barlesi, MD

Patients with ROS1-positive non—small cell lung cancer (NSCLC) showed high response rates and durable responses following treatment with entrectinib, according to findings from a pooled analysis of 3 studies presented at the 2019 European Lung Cancer Congress.

Entrectinib demonstrated systemic efficacy with 77.4% of patients in the overall population showing a response. Strong intracranial activity was also demonstrated in a cohort of patients with CNS disease at baseline who showed an overall response rate (ORR) of 73.9%.

“There are high unmet needs in patients with ROS fusion—positive NSCLC. Brain metastases are common in this population and the CNS is a common site of first progression, therefore use of a CNS-penetrant ROS-1 inhibitor in the first-line setting would be beneficial to these patients,” said Fabrice Barlesi MD, PhD, Marseille University, Assistance Publique-Hopital du Marseille in Marseille, France.

Entrectinib is a potent ROS1 inhibitor that also inhibits TRKA/B/C. Entrectinib was designed to cross the blood-brain barrier and effectively penetrate the CNS to achieve therapeutic levels in the CNS, Barlesi explained.

“In preclinical studies, entrectinib provided more potent ROS1 inhibition than crizotinib, “ he noted.

Barlesi presented results from an integrated efficacy analysis from two phase I entrectinib studies—ALKA-372-001 (EudraCT 2012-000148-88] and STARTRK-1 (NCT02097810)—and the phase II STARTRK-2 (NCT02568267) trial. Based on data from this analysis, the FDA is currently reviewing a new drug application (NDA) for entrectinib as a treatment for patients with metastatic ROS1-positive NSCLC, as well as patients with NTRK fusion—positive locally advanced or metastatic solid tumors. The action date for a decision on the NDA is August 18, 2019.

The 3 trials enrolled patients with NSCLC who had not received prior treatment with a ROS1 inhibitor but harbored a ROS1 fusion, as determined by nucleic acid—based diagnostic platforms. Tumor assessments were done at week 4 and every 8 weeks thereafter by blinded independent central review (BICR; by RECIST v1.1).

The efficacy population comprised 53 patients with a median age of 53 years (range, 27-73). Sixty-four percent of patients were female, 50.9% were ECOG performance status 1, and 58.5% were never-smokers. At baseline, 43.4% of patients had CNS disease.

The safety-evaluable population included 134 patients who received ≥1 dose of entrectinib and had at least 6 months of follow-up. Patient characteristics were similar in this cohort, with the exception that more (50.0%) patients had CNS disease at baseline.

The primary endpoints of all the studies were ORR and duration of response (DOR). Key secondary endpoints included progression-free survival (PFS) and safety. Additional endpoints were intracranial ORR, DOR in patients with intracranial response, and PFS in patients with or without baseline CNS disease.

The ORR of 77.4% in the overall population included 3 (5.7%) patients with a complete response (CR), and the median DOR was 24.6 months (95% CI, 11.4-34.8). The clinical benefit rate was 77.4% (95% CI, 83.8-87.7). In patients with CNS disease, the ORR was 73.9%, with no CRs observed. The median DOR was 12.6 months (95% CI, 6.5-NE).

Median PFS in the overall and CNS-positive cohorts was 19.0 months (95% CI, 12.2-36.6) and 13.6 months (95% CI 4.5-NE), respectively. Overall survival data were not yet mature with a median follow-up of 15.5 months.

The intracranial ORR by BICR assessment was 55% (95% CI, 31.5-76.9), including a CR rate of 20% (n = 4) and a partial response rate of 35% (n = 7). No cases of stable disease were observed. Disease progression occurred in 15% of patients and 30% of patients were nonevaluable. In patients showing an intracranial response, the median DOR was 12.9 months.

“Entrectinib is well tolerated with a manageable safety profile,” Barlesi said. “Most adverse events were grades 1 or 2.”

In the ROS1 safety-evaluable population, at least 1 treatment-related adverse event (TRAE) of any grade was seen in 93% of patients. The most commonly reported TRAEs were dysgeusia (42.5%), dizziness (32.8%), and constipation (32.8%%). TRAEs grade ≥3 included weight gain, which occurred in 7.5% of patients; diarrhea in 2.2%; myalgia and aspartate aminotransferase increase in 1.5% of patients each; and dysgeusia, dizziness, and blood creatinine increase in 0.7% of patients each. There were no grade 5 TRAEs. TRAEs led to dose reduction or discontinuation in 34% and 5% of patients, respectively.

“Entrectinib is highly active in patients with ROS1-positive NSCLC with and without CNS disease; entrectinib demonstrated clinically meaningful deep and durable systemic and intracranial responses,” concluded Barlesi.

Barlesi F, Drilon A, De Braud F, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non—small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Presented at: 2019 European Lung Cancer Congress; April 11 to 13, 2019; Geneva, Switzerland. Abstract 109O.

<<< 2019 European Lung Cancer Congress

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania